Tiger Brokers

Monopar Therapeutics FY2025 net loss narrows 12% to $(13.7) million; interest income jumps more than 6x to $3.0 million

Reuters
Mar 28
<a href="https://laohu8.com/S/MNPR">Monopar Therapeutics</a> FY2025 net loss narrows 12% to $(13.7) million; interest income jumps more than 6x to $3.0 million
  • Monopar published its annual report on Form 10-K, reporting a net loss of USD 13.7 million and an operating loss of USD 16.7 million.
  • Research and development expense fell 23.85% to USD 9.9 million, driven mainly by the absence of one-time 2024 ALXN1840 in-licensing costs and lower radiopharmaceutical trial costs, partly offset by higher personnel and manufacturing spending.
  • General and administrative expense rose more than doubled to USD 6.8 million, primarily reflecting higher board and personnel compensation and increased patent legal and other costs.
  • Interest income increased more than doubled to USD 3.0 million, attributed to interest earned on U.S. Treasury securities and commercial paper and higher bank balances following the September 2025 capital raise.
  • Cash, cash equivalents and investments totaled USD 140.4 million as of Dec. 31, 2025, and management said it expects current funds to be sufficient at least through Dec. 31, 2027 while it targets a mid-2026 NDA submission for ALXN1840 and advances MNPR-101 radiopharmaceutical programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010025), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10